CABOMETYX® (cabozantinib) Abbreviations

CABOMETYX® (cabozantinib) Abbreviations


(a)HCC (advanced) Hepatocellular Carcinoma
(a)RCC (advanced) Renal Cell Carcinoma
(HR)QoL (Health Related) Quality of Life
(m)RECIST (modified) Response Evaluation Criteria In Solid Tumors
AE Adverse Event
AFP Alpha FetoProtein
AASLD American Association for the Study of Liver Disease
ASCO American Society of Clinical Oncology
A-Pac Asia Pacific
A&U Awareness and Usage
BCLC Barcelona Clinic Liver Cancer
BSC Best Supportive Care
BMS Bristol Myers Squibb
BU Business Unit
CRPC Castration Resistant Prostate Cancer
CPI Check Point Inhibitor
CM CheckMate
CP-A Child Pugh-A
CSR Clinical Study Report
CHMP Committee for Medicinal Products for Human Use
CT-Scan Computed Tomography Scan
CME Continuing Medical Education
CSF Critical Success Factor
DCR Disease Control Rate
DoT Duration of Treatment
ECOG Eastern Cooperative Oncology Group
ER Emergency
EASL European Association for the Study of the Liver
EAU European Association of Urology
EC European Commission
EFPIA European Federation of Pharmaceutical Industries and Associations 
EIKCS European International Kidney Cancer Symposium
ELPA European Liver Patient Association
EMA European Medicine Agency
ESMO European Society of Molecular Oncology
EU European Union
G-BA German Federal Joint Committee
1L / 2L First line / Second Line
FPI First Patient In
FDA Food and Drug Administration
FYROM Former Yugoslavian Republic of Macedonia
EU5 France, Germany, Italy, Spain, UK
EU3 France, Germany, UK
GI Gastro Intestinal
GE GastroEnteric
GU GenitoUrinary
DACH Germany, Austria, Switzerland
GCSP Globcal Cabometyx Strategic Plan
GAS-6 Growth arrest-specific 6 (AXL ligand)
HAS Haute Autorité de Santé (French National Authority for Health)
HR Hazard Ratio
HCP Health Care Provider
HEOR Health Economics Outcome Research
HTA Health Technology Assessment
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HGF Hepatocyte Growth Factor (MET ligand)
MET Hepatocyte growth factor receptor
HEP Hepatologists
IME Independent Medical Education
IRC Independent Review Committee
IDO-1 Indoleamine-pyrrole 2,3-dioxygenase
IKCC International Kidney Cancer Coalition
ILCA International Liver Cancer Association
IIME Ipsen Initiated Medical Education
ISS Ipsen Sponsored Study
KAM Key Account Manager
KPI Key Performance Indicator
LPI Last Patient In
LPLV Last Patient Last Visit
LCM Life Cycle Management
LDT Liver Directed Therapies
mToR mammalian Target of Rapamycin
MEA Managed Entry Agreement
MoA Mechanism of Action
MTC Medullary Thyroid Cancer
MSD Merck Sharp and Dohme
MC(M) MultiChannel (Marketing)
NICE National Institute for Health and Care Excellence
NMA Network Meta Analysis
NIS Non Interventional Study
NSCLC Non Small Cell Lung Cancer
Nordics Norway, Sweden, Finland, Denmark
NA Not Available
NR Not Reached
ISPOR International Society for Pharmacoeconomics and Outcomes Research
ORR Objective Response Rate
ONC Oncologists
OS Overall Survival
PVP Payer Value Proposition
PS Performance status
PK PhamacoKinetic
PDF Portable Document File
P&R Price & Reimbursement
P&MA Pricing & Market Access
PCP Primary Care Provider
PE Primary Endpoint
PI Principal Education
PFS Progression Free Survival
Q&A Question and Answers
RET Rearranged during transfection (proto oncogene)
R&D Research & Development
RoW Rest of the World
ROI Return on Investment
SoC Standard of Care
T/C Teleconference
TL Thought Leader
TBC To Be Confirmed
TBD To Be Determined
Tx Treatment
Rx Prescription Treatment
TRAE Treatment Related Adverse Events
TKI Tyrosine Kinase Inhibitor
USA United States of America
UC Urothelial Cancer
VEGF(R) Vascular Endothelial Growth Factor (Receptor)
WG Working group
WCGI World Congress on GI Cancer
WKCD World Kidney Cancer Day
© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to website. This website is intended for Sweden Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.